[Tendency of development on novel type of cardiotonic drugs].
The narrow margin of safety of cardiotonic glycosides has led to extensive studies for novel cardiotonic agents that are superior to the glycosides. Cardiotonic drugs acting on beta-adrenoceptors and inhibitors of cAMP phosphodiesterase have been extensively studied and used for the treatment of heart failure. Ca sensitizers are of interest, since such a mechanism of action may be beneficial for the failing heart. Recently, cardiotonic substances with a novel mechanism of action such as gingerol and xestoquinone have been isolated from natural sources. Furthermore, 9-methyl-7-bromoeudistomin D, a powerful radiolabeled Ca2+ releaser having caffeine-like properties, may provide a promising tool for studying the molecular mechanism of the Ca2+ release process.
Ohizumi
Y
Y
Department of Pharmaceutical Molecular Biology, Tohoku University.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000676:Amrinone / Q000627:therapeutic use; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002396:Catechols; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D005233:Fatty Alcohols / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D011724:Pyridazines / Q000627:therapeutic use; D014336:Troponin / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D002396:Catechols; D005233:Fatty Alcohols; D011724:Pyridazines; D014336:Troponin; D004280:Dobutamine; C007845:gingerol; C052228:MCI 154; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000676:Amrinone; D002118:Calcium; D004298:Dopamine